Supporting Information

Efficient Synthesis of Biazoles by Aerobic Oxidative Homocoupling of Azoles

Catalyzed by Copper(I) / 2-pyridonate Catalytic System

Mingwen Zhu,^a Ken-ichi Fujita,^{*,a,b} and Ryohei Yamaguchi^{*,a}

^aGraduate School of Human and Environmental Studies, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan

Email: yamaguchi.ryohei.8c@kyoto-u.ac.jp

^bGraduate School of Global Environmental Studies, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan

Email: fujitak@kagaku.mbox.media.kyoto-u.ac.jp;

Experimental Section:	S2
General	S2
Preparation of 2-pyridonate ligands	S2
Procedure for the homocoupling of 1-methyl-1 <i>H</i> -imidazole shown in Table 1	S2
Gerneral Procedure for the oxidative homocoupling of various azoles shown	in Table 2
and 3	S3
Stoichiometric reaction of CuCl with sodium 5-methyl-2-pyridonate (L8)	to afford
copper compound 21	S3
¹ H NMR spectra of copper compound 21 and free ligand L8 in D ₂ O	S4
Aerobic oxidative homocoupling of N-methylimidazole catalyzed by t	he copper
compound 21	S4
Explanation of a Plausible Mechanism	S5
Data for the Products of oxidative homocoupling of azoles	S6
X-ray Structure Analysis of 14a	
¹ H and ¹³ C NMR spectra of biazole products 1a-20a	S10

Experimental Section:

General: All reactions and manipulations were carried out by means of standard Schlenk techniques. ¹H and ¹³C NMR spectra were recorded on JEOL ECS-400 and ECX-500 spectrometers. Column chromatography was carried out by using Wako-gel C-200. Elemental analyses were carried out at the Microanalysis Center of Kyoto University. Melting points were measured using a Yanagimoto melting point measurement apparatus. Solvents were dried procedures distilled by standard and prior to use. 1-(4-methylbenzyl)-1*H*-imidazole 1-(4-trifluorobenzyl)-1*H*-imidazole (8), (9), 1-(4-bromobenzyl)-1H-1-(4-chlorobenzyl)-1*H*-imidazole imidazole (10),(11),1-(3-chlorobenzyl)-1*H*-imidazole (12), 1-(2-chlorobenzyl)-1*H*-imidazole (13), were prepared according to the literature method¹. All other reagents are commercially available and were used without further purification.

Preparation of 2-pyridonate ligands: To an oven-dried, argon purged flask were added 1.0 mmol of functionalized hydroxypyridine (2-hydroxypyridine, 3-hydroxypyridine, 4-hydroxypyridine, phenol, 5-trifluoromethyl-2-hydroxypyridine, 5-nitro-2-hydroxypyridine, 6-methyl-2-hydroxypyridine, 5-methyl-2-hydroxypyridine, 4-methyl-2-hydroxypyridine, 3-methyl-2-hydroxypyridine, 1.0 mmol of sodium ethoxide and ethanol (2.5 mL), respectively. The mixture was stirred at room temperature for 2 hours. Then the solvent was removed and residue was dried in vacuo to give a colorless or yellow solid.

Sodium 2-pyridonate (L1) ¹H NMR (500 MHz, D₂O): δ 7.72 (br, 1H, Ar-H), 7.55 (t, 1H, J = 8.0 Hz, Ar-H), 6.54 (t, 1H, J = 5.3 Hz, Ar-H), 6.47 (d, 1H, J = 7.5 Hz, Ar-H).

Sodium 3-methoxy-2-pyridonate (L5) ¹H NMR (400 MHz, D₂O): δ 7.17 (br, 1H, Ar-H), 7.04 (d, 1H, *J* = 7.6 Hz, Ar-H), 6.47 (br, 1H, Ar-H), 3.76 (s, 3H, OCH₃).

Sodium 3-methyl-2-pyridonate (L6) ¹H NMR (400 MHz, D₂O): δ 7.50 (d, 1H, *J* = 5.2 Hz, Ar-H), 7.44 (d, 1H, *J* = 5.2 Hz, Ar-H), 6.47 (t, 1H, *J* = 5.2 Hz, Ar-H), 2.06 (s, 3H, CH₃).

Sodium 4-methyl-2-pyridonate (L7) ¹H NMR (500 MHz, D₂O): δ 7.50 (d, 1H, J = 6.0 Hz, Ar-H), 6.43 (d, 1H, J = 6.0 Hz, Ar-H), 6.37 (br, 1H, Ar-H), 2.22 (s, 3H, CH₃).

Sodium 5-methyl-2-pyridonate (L8) ¹H NMR (500 MHz, D_2O): δ 7.55 (s, 1H, Ar-H), 7.44 (d, 1H, J = 9.0 Hz, Ar-H) 6.43 (d, 1H, J = 8.5 Hz, Ar-H), 2.12 (s, 3H, CH₃).

Sodium 6-methyl-2-pyridonate (**L9**) ¹H NMR (500 MHz, D₂O): δ 7.49 (br, 1H, Ar-H), 6.39 (br, 1H, Ar-H), 6.31 (br, 1H, Ar-H), 2.27 (br, 3H, CH₃).

Sodium 5-(trifluoromethyl) -2-pyridonate (L10) ¹H NMR (400 MHz, D₂O): δ 8.08 (s, 1H, Ar-H), 7.61 (d, 1H, J = 7.2 Hz, Ar-H), 6.38 (d, 1H, J = 7.2 Hz, Ar-H).

Sodium 5-nitro-2-pyridonate (L11) ¹H NMR (500 MHz, D₂O): δ 8.84 (br, 1H, Ar-H), 8.18 (br, 1H, Ar-H), 6.39 (br, 1H, Ar-H).

Procedure for the homocoupling of 1-methyl-1*H***-imidazole shown in Table 1:** To an oven-dried, argon purged two-necked flask were added sodium 2-pyridonate (0.04 mmol, 2.0 or 1.0 mol%), Cu-catalyst (0.02 mmol, 2.0 or 1.0 mol%), 1-methyl-1*H*-imidazole (1.0 or 2.0 mmol), and *p*-xylene (4 mL). The flask was sealed and preheated at 140 °C under argon for

about 1 minute and then the mixture was stirred at 140 °C under open air for 20 h. The mixture was cooled to room temperature. The solvent was removed in vacuo and the crude reaction mixture was diluted with chloroform and filtered through a filter-paper. Chloroform was removed in vacuo and 1,3,5-trimethoxybenzene was added as an internal standard for NMR analysis. The yield of 1,1'-dimethyl-1H,1H'-2,2'-biimidazole (1) was calculated by ¹H-NMR analysis in chloroform-d.

General Procedure for the oxidative homocoupling of various azoles shown in Table 2 and 3: To an oven-dried, argon purged flask were added sodium 5-methyl-2-pyridonate (L8) (0.04 mmol, 2.0 mol%), CuCl (0.02 mmol, 1.0 mol%), an azole (2.00 mmol) and *p*-xylene (4 mL). The flask was sealed and preheated at 140 °C under argon for about 1 minutes and then the mixture was stirred at 140 °C under open air for 20 h. The mixture was cooled to room temperature. The solvent was removed in vacuo and the crude reaction mixture was diluted with chloroform and filtered through a filter-paper. The filtrate was concentrated by evaporation and purified by a silica gel column chromatography.

Stoichiometric reaction of CuCl with sodium 5-methyl-2-pyridonate (L8) to afford copper compound 21:



To an oven-dried, argon purged two-necked flask were added CuCl (1.5 mmol), sodium 5-methyl-2-pyridonate (1.5 mmol) and *p*-xylene (10 mL). The suspension was heated under reflux in an oil bath for 2 h under argon. Then the mixture was cooled to room temperature and washed with, MeOH, (5 mL, 2 times) and Et₂O (5 mL, 2 times) . Drying in vacuum gave a yellow solid (**21**) (229.1 mg, 89%). M. p.: 192 °C (dec.). ¹H NMR (500 MHz, D₂O) δ 7.65 (d, 1H, *J* = 9.0 Hz), 7.37 (s, 1H), 6.61 (d, 1H, *J* = 9.5 Hz), 2.15 (s, 3H). ¹³C NMR (125.7 MHz, D₂O) δ 163.7, 146.5, 132.5, 119.3, 118.2, 16.0. Anal.Calcd for CuC₆H₆NO: C, 41.98; H, 3.52; N, 8.16. Found: C, 41.74; H, 3.53; N, 8.11.



¹H NMR spectra of copper compound 21 and free ligand L8 in D₂O:

Aerobic oxidative homocoupling of N-methylimidazole catalyzed by the copper compound 21:



To an oven-dried, argon purged two-necked flask were added the copper compound **21** (3. 2 mg, 2.0 mol% Cu), 1-methyl-1*H*-imidazole (2.00 mmol), and *p*-xylene (4 mL). The flask was sealed and preheated at 140 °C under argon for about 1 minute and then the mixture was stirred at 140 °C under open air for 20 h. The mixture was cooled to room temperature. The solvent was removed in vacuo and the crude reaction mixture was diluted with chloroform and filtered through a filter-paper. Chloroform was removed in vacuo and 1,3,5-trimethoxybenzene was added as an internal standard for NMR analysis. The yield of 1,1'-dimethyl-1*H*,1*H*'-2,2'-biimidazole (**1a**) was calculated by the integration in ¹H-NMR analysis in chloroform-d.

Explanation of a Plausible Mechanism:

Although the mechanism for the CuCl/2-pyridonate catalyzed aerobic oxidative homo-coupling of azoles is not completely clear so far, a plausible one is shown in Scheme S1. The reaction would start with the formation of a Cu(I) species **A** bearing 2-pyridonate as a ligand by the reaction of CuCl with sodium 2-pyridonate. Then, 2-pyridonate ligand-promoted C-H activation of azole would occur to afford a Cu(I) species **B** which would be oxidized by oxygen to form a Cu(III)-oxo species **C**. Subsequent hydrogen transfer from hydroxyl group in the ligand to copper-oxo moiety would occur to afford a Cu(III) species **D**. Ligand promoted C-H activation of azole followed by dehydration would proceed to give a bis-imidazolyl Cu(III) species **E**. Reductive elimination would take place to give the corresponding biazoles and regenerate the Cu(I) species **A**.



Scheme S1. A plausible mechanism

Data for the Products of oxidative homocoupling of azoles:

1,1'-dimethyl-1H,1H'-2,2'-biimidazole (1a)²:

Purification was performed by column chromatography on silica gel eluting with EtOAc (100%) to give **1a** as a colorless solid (152.2 mg, 95% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.11 (d, 2H, J = 1.0 Hz, Im-H), 6.96 (d, 2H, J = 1.0 Hz, Im-H), 4.04 (s, 6H, CH₃). ¹³C NMR (125.7 MHz, CDCl₃) δ 138.82, 127.96, 122.74, 35.49.

1,1'-diethyl-1H,1H'-2,2'-biimidazole (**2a**)³:

Purification was performed by column chromatography on silica gel eluting with EtOAc/Hexane (3:1) to give product **2a** as a colorless solid (182.2 mg, 96% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.12 (d, 2H, J = 1.0 Hz, Im-H), 7.02 (d, 2H, J = 1.0 Hz, Im-H), 4.50 (q, 4H, J = 7.5 Hz, CH₂), 1.41 (t, 6H, J = 7.5 Hz, CH₃). ¹³C NMR (125.7 MHz, CDCl₃) δ 138.04, 128.24, 120.56, 42.63, 16.63.

1,1'-di-n-butyl-1*H*,1*H*'-2,2'-biimidazole (**3a**)³:

Purification was performed by column chromatography on silica gel eluting with EtOAc/Hexane (1:1) to give **3a** as a pale yellow oil (221.0 mg, 90% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.11 (s, 2H, Im-H), 6.99 (s, 2H, Im-H), 4.44 (t, 4H, J = 7.5 Hz, CH₂CH₂CH₂CH₃), 1.74-1.68 (m, 4H, CH₂CH₂CH₂CH₃), 1.30-1.25 (m, 4H, CH₂CH₂CH₂CH₃), 0.89-0.86 (t, 6H, J = 7.5 Hz, CH₃). ¹³C NMR (125.7 MHz, CDCl₃) δ 138.24, 128.05, 47.20, 33.25, 19.81, 13.73.

1,1'-divinyl-1*H*,1*H*'-2,2'-biimidazole (**4a**):

Purification was performed by column chromatography on silica gel eluting with EtOAc/Hexane (1:1) to give **4a** as a colorless solid (117.5 mg, 63% yield). M. p.: 125-126°C, ¹H NMR (500 MHz, CDCl₃): δ 8.02 (q, 2H, *J* = 8.0 Hz, C*H*=CH₂), 7.37 (d, 2H, *J* = 1Hz, Im-H), 7.17 (d, 2H, *J* = 1 Hz, Im-H), 5.28 (dd, 2H, *J* = 16.0 Hz, 1.5 Hz, CH=CH₂), 4.95 (dd, 2H, *J* = 8.0 Hz, *J* = 1.5 Hz, CH=CH₂). ¹³C NMR (125.7 MHz, CDCl₃) δ 137.3, 131.3, 129.6, 117.1, 102.5. Anal.Calcd for C₁₀H₁₀N₄: C, 64.50; H, 5.41; N, 30.09. Found; C, 64.59; H, 5.38; N, 30.04.

1,1'-di(4-methoxyphenyl)-1H,1H'-2,2'-biimidazole (**5a**)⁴:

Purification was performed by column chromatography on silica gel eluting with EtOAc (100%) to give **5a** as a colorless solid (266.1 mg, 77% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.22 (d, 2H, J = 1.0 Hz, Im-H), 7.02 (d, 2H, J = 1.0 Hz, Im-H), 6.75-6.70 (m, 8H, Ar-H), 3.79 (s, 6H, CH₃). ¹³C NMR (125.7 MHz, CDCl₃) δ 158.95, 137.81, 130.45, 129.73, 125.60, 121.63, 114.26, 55.67.

1,1'-dibenzyl-1H,1H'-2,2'-biimidazole (7**a**)²:

Purification was performed by column chromatography on silica gel eluting with EtOAc/Hexane (1:1) to give **7a** as a pale yellow solid (291.6 mg, 92% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.24-7.23 (m, 6H, Ar-H), 7.12 (d, 2H, J = 1.0 Hz, Im-H), 7.04-7.03 (m, 4H, Ar-H), 6.93 (d, 2H, J = 1.0 Hz, Im-H), 5.71 (s, 4H, CH₃). ¹³C NMR (125.7 MHz, CDCl₃) δ

138.41, 137.46, 128.80, 128.53, 127.76, 127.58, 121.57, 50.94.

1,1'-di(4-methylbenzyl)-1*H*,1*H*'-2,2'-biimidazole (8a):

Purification was performed by column chromatography on silica gel eluting with EtOAc (100%) to give **8a** as a pale red solid (294.2 mg, 86% yield). M.p.: 154-155 °C, ¹H NMR (500 MHz, CDCl₃) δ 7.12 (s, 2H, Im-H), 7.04 (d, 4H, J = 7.5 Hz, Ar-H), 6.94-6.92 (m, 6H, Ar-H and Im-H), 5.63 (s, 4H, CH₂), 2.31 (s, 6H, CH₃). ¹³C NMR (125.7 MHz, CDCl₃) δ 138.43, 137.48, 134.44, 129.46, 128.47, 127.69, 121.48, 50.75, 21.27. Anal. Calcd for C₂₂H₂₂N₄: C, 77.16; H, 6.48; N, 16.36. Found: C, 77.39; H, 6.31; N, 16.45.

1,1'-di(4-trifluoromethylbenzyl)-1*H*,1*H*'-2,2'-biimidazole (**9a**):

Purification was performed by column chromatography on silica gel eluting with EtOAc/Hexane (1:1) to give **9a** as a pale red solid (379.7 mg, 88% yield). M.p.: 122-123 °C, ¹H NMR (500 MHz, CDCl₃) δ 7.49 (d, 4H, *J* = 8.0 Hz, Ar-H), 7.15-7.13 (m, 6H, Ar-H and Im-H), 6.95 (d, 2H, *J* = 1.0 Hz, Im-H), 5.85 (s, 4H, CH₂). ¹³C NMR (125.7 MHz, CDCl₃) δ 141.54, 138.25, 130.10 (q, *J* = 32.8 Hz, C-F coupling), 128.86, 127.65, 125.76, 124.08 (q, *J* = 271.8 Hz, C-F coupling), 121.85, 50.56. Anal. Calcd for C₂₂H₁₆F₆N₄: C, 58.67; H, 3.58; N, 12.44. Found: C, 59.14; H, 3.93; N, 12.07.

1,1'-di(4-bromobenzyl)-1*H*,1*H*'-2,2'-biimidazole (**10a**):

Purification was performed by column chromatography on silica gel eluting with EtOAc/Hexane (1:1) to give **10a** as a pale yellow solid (414.9 mg, 90% yield). M.p.: 149-150 $^{\circ}$ C, ¹H NMR (500 MHz, CDCl₃) δ 7.36 (d, 4H, *J* = 8.0 Hz, Ar-H), 7.12 (d, 2H, *J* = 1.0 Hz, Im-H), 6.93 (s, 2H, *J* = 1.0 Hz, Im-H), 6.88 (d, 4H, *J* = 8.0 Hz, Ar-H), 5.66 (s, 4H, CH₂). ¹³C NMR (125.7 MHz, CDCl₃) δ 138.20, 136.46, 131.92, 129.24, 128.66, 121.83, 121.68, 50.37. Anal. Calcd for C₂₂H₁₆Br₂N₄: C, 50.87; H, 3.42; N, 11.87. Found: C, 50.89; H, 3.38; N, 11.54.

1,1'-di(4-chlorobenzyl)-1*H*,1*H*'-2,2'-biimidazole (**11a**):

Purification was performed by column chromatography on silica gel eluting with EtOAc (100%) to give **11a** as a pale yellow solid (348.1 mg, 90% yield). M.p.:161-162 °C, ¹H NMR (500 MHz, CDCl₃) δ 7.20 (d, 4H, J = 8.0 Hz, Ar-H), 7.12 (d, 2H, J = 1.5 Hz, Im-H), 6.95 (d, 4H, J = 8.0 Hz, Ar-H), 6.93 (d, 2H, J = 1.5 Hz, Im-H), 5.68 (s, 4H, CH₂). ¹³C NMR (125.7 MHz, CDCl₃) δ 138.21, 135.96, 133.71, 128.96, 128.94, 128.67, 121.65, 50.32. Anal. Calcd for C₂₂H₁₆Cl₂N₄: C, 62.67; H, 4.21; N, 14.62. Found; C, 62.73; H, 4.22; N, 14.67.

1,1'-di(3-chlorobenzyl)-1*H*,1*H*'-2,2'-biimidazole (**12a**):

Purification was performed by column chromatography on silica gel eluting with EtOAc (100%) to give **12a** as a pale yellow solid (318.4 mg, 83% yield). M.p.: 106-107 °C, ¹H NMR (500 MHz, CDCl₃) δ 7.23-7.10 (m, 8H, Ar-H and Im-H), 6.92-6.94 (m, 4H, Ar-H and Im-H), 5.73 (s, 4H, CH₂) ¹³C NMR (125.7 MHz, CDCl₃) δ 139.49, 138.25, 134.69, 130.15, 128.76, 128.09, 127.70, 125.67, 121.69, 50.44. Anal. Calcd for C₂₂H₁₆Cl₂N₄: C, 62.67; H, 4.21; N, 14.62. Found: C, 62.46; H, 4.37; N, 14.59.

1,1'-di(2-chlorobenzyl)-1*H*,1*H*'-2,2'-biimidazole (**13a**):

Purification was performed by column chromatography on silica gel eluting with EtOAc (100%) to give **13a** as a pale yellow solid (313.1 mg, 81% yield). M.p.: 157-158 °C, ¹H NMR (500 MHz, CDCl₃) δ 7.37 (d, 2H, *J* = 8.0 Hz, Ar-H), 7.21 (t, 2H, *J* = 7.5 Hz, Ar-H), 7.12 (s, 2H, Im-H), 7.11 (t, 2H, *J* = 7.5 Hz, Ar-H), 6.95 (s, 2H, Im-H), 6.87 (d, 2H, *J* = 8.0 Hz, Ar-H), 5.89 (s, 4H, CH₂). ¹³C NMR (125.7 MHz, CDCl₃) δ 138.58, 135.27, 133.26, 129.73, 129.34, 129.19, 128.72, 127.34, 121.66, 48.67. Anal. Calcd for C₂₂H₁₆Cl₂N₄: C, 62.67; H, 4.21; N, 14.62. Found: C, 62.67; H, 4.17; N, 14.54.

1,1'-dimethyl-1H,1H'-2,2'-bibenzo[d]imidazole (14a)²:

Purification was performed by column chromatography on silica gel eluting with EtOAc/Hexane (1:5) to give **14a** as a colorless solid (224.1 mg, 85% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.88 (d, 2H, *J* = 8.0 Hz, Ar-H), 7.48 (d, 2H, *J* = 8.0 Hz, Ar-H), 7.42-7.35 (m, 4H, Ar-H), 4.32 (s, 6H, CH₃). ¹³C NMR (125.7 MHz, CDCl₃) δ 143.36, 142.68, 136.33, 124.06, 122.98, 120.43, 110.21, 32.56.

4,4'-diphenyl-2,2'-bioxazole (15a):

Purification was performed by column chromatography on silica gel eluting with EtOAc/Hexane (1:5) to give product **15a** as a colorless solid (241.9 mg, 84% yield). M.p.: 249-250 °C, ¹H NMR (500 MHz, CDCl₃) δ 8.11 (s, 2H, Im-H), 7.87 (d, 4H, *J* = 7.5 Hz, Ar-H), 7.46 (t, 4H, *J* = 7.5 Hz, Ar-H), 7.38 (t, 2H, *J* = 7.5 Hz, Ar-H). ¹³C NMR (125.7 MHz, CDCl₃) δ 151.32, 142.97, 135.12, 129.94, 128.95, 128.89, 125.97. Anal. Calcd for C₁₈H₁₂N₂O₂: C, 74.99; H, 4.20; N, 9.72. Found: C, 75.39; H, 4.48; N, 9.45.

2,2'-bibenzo[d]oxazole $(16a)^2$:

Purification was performed by column chromatography on silica gel eluting with EtOAc/Hexane (1:5) to give product **16a** as a colorless solid (216.4 mg, 92% yield). ¹H NMR (500 MHz, CDCl₃) δ 7.93 (d, 2H, J = 8.0 Hz, Ar-H), 7.73 (d, 2H, J = 8.0 Hz, Ar-H), 7.55–7.47 (m, 4H, Ar-H). ¹³C NMR (125.7 MHz, CDCl₃) δ 152.03, 151.13, 141.31, 127.70, 125.92, 121.67, 111.63.

2,2'-bibenzo[*d*]thiazole (17a):

Purification was performed by column chromatography on silica gel eluting with EtOAc (100%) to give **17a** as a colorless solid (218.2 mg, 81% yield). M.p.: 239-240 °C (dec.), ¹H NMR (500 MHz, CDCl₃) δ 8.17 (d, 2H, J = 8.0 Hz, Ar-H), 8.00 (d, 2H, J = 8.0 Hz, Ar-H), 7.57 (t, 2H, J = 7.0 Hz, Ar-H), 7.50 (t, 2H, J = 7.0 Hz, Ar-H). ¹³C NMR (125.7 MHz, CDCl₃) δ 161.63, 153.65, 135.90, 126.94, 126.73, 124.18, 122,14. Anal.Calcd for C₁₄H₈N₂S₂: C, 62.66; H, 3.00; N, 10.44. Found: C, 62.63; H, 2.97; N,10.42.

4,4'-dimethyl-2,2'-bithiazole (18a)²:

Purification was performed by column chromatography on silica gel eluting with EtOAc/Hexane (1:5) to give **18a** as a pale green solid (180.9 mg, 91% yield). ¹H NMR (500 MHz, CDCl₃) δ 6.96 (s, 4H, Im-H), 2.51 (s, 6H, CH₃). ¹³C NMR (125.7 MHz, CDCl₃) δ 160.96, 154.30, 115.56, 17.32.

4,4',5,5'-tetramethyl-2,2'-bithiazole (**19a**)²:

Purification was performed by column chromatography on silica gel eluting with EtOAc/Hexane (1:5) to give **19a** as a colorless solid (209.1 mg, 92% yield). ¹H NMR (500 MHz, CDCl₃) δ 2.39 (s, 6H, CH₃), 2.36 (s, 6H, CH₃). ¹³C NMR (125.7 MHz, CDCl₃) δ 157.23, 149.68, 128.30, 14.96, 11.76.

(4,4'-dimethyl-2,2'-bithiazole-5,5'-diyl)bis(methylene) dipropionate (20a):

Purification was performed by column chromatography on silica gel eluting with EtOAc/Hexane (1:1) to give **20a** as a colorless solid (367.6 mg, 98% yield). M.p.: 118-119 °C. ¹H NMR (500 MHz, CDCl₃) δ 4.26 (t, 4H, OCH₂), 3.10 (t, 4H, Im-CH₂), 2.41 (s, 6H, Im-CH₃), 2.08 (s, 6H, COCH₃). ¹³C NMR (125.7 MHz, CDCl₃) δ 170.97, 158.36, 150.74, 129.34, 64.04, 26.31, 21.08, 15.20. Anal. Calcd for C₁₆H₂₀N₂O₄S₂: C, 52.15; H, 5.47; N, 7.66. Found: C, 52.11; H, 5.43; N, 7.59.

X-ray Structure Analysis of 14a: Diffraction data for **14a** were obtained with a Rigaku RAXIS RAPID instrument. Reflection data were corrected for Lorentz and polarization effects. Empirical absorption corrections were applied. The structures was solved by direct method^{5,6} and refined anisotropically for non-hydrogen atoms by full-matrix least-squares calculations. Atomic scattering factors and anomalous dispersion terms were taken from the literature.⁷ Hydrogen atoms were located on the idealized positions. The calculations were performed using the program system CrystalStructure.^{8,9} ORTEP drawing of **14a** is shown in Figure S1. The crystal data and details are shown in CIF file.



Figure S1. ORTEP drawings of 1,1'-dimethyl-1H,1H'-2,2'-bibenzo[d]imidazole (14a) with 50% thermal probability ellipsoids.



























































Reference:

1. L. Roumen, J. W. Peeters, J. M. A. Emmen, I. P. E. Beugels, E. M. G. Custers, M. de Gooyer, R. Plate, K. Pieterse, P. A. J. Hilbers, J. F. M. Smits, J. A. J. Vekemans, D. Leysen, H. C. J. Ottenheijm, H. M. Janssen, and J. J. R. Hermans, *J. Med. Chem.*, 2010, **53**, 1712.

2. Y. Li, J. Jin, W. Qian and W. Bao, Org. Biomol. Chem., 2010, 8, 326.

3. J. Xiao and J. M. Shreeve, J. Org. Chem., 2005, 70, 3072.

4. K. Stippich, R. Kretschmer, R. Beckert and H. Goerls, Synthesis, 2010, 14, 1311

5. P. T. Beurskens, G. Admiraal, G. Beurskens, W. P. Bosman, R. de Gelder, R. Israel and J. M. M. Smits, The DIRDIF-99 program system, Technical Report of the Crystallography

Laboratory University of Nijmegen, Nijmegen, The Netherlands, 1999.

6. A. Altomare, G. Cascarano, C. Giacovazzo, A. Guagliardi, M. Burla, G. Polidori and M. Camalli, *J. Appl. Crystallogr.*, 1994, **27**, 435.

7. (a) D. T. Cromer, G. T. Waber, International Table for X-Ray Crystallography, The Kynoch Press, Birmingham, U.K., 1974; vol. IV, table 2.2 A; (b) J. A. Ibers, W. C. Hamilton, *Acta Crystallogr.*, 1964, **17**, 871; (c) D. C. Creagh, W. J. McAuley, in International Tables for X-Ray Crystallography, ed. A. J. C. Wilson, Kluwer Academic Publishers, Boston, 1992; vol. C, pp. 219–222, table 4.2.6.8; (d) D. C. Creagh, J. H. Hubbell, in International Tables for X-Ray Crystallography, ed. A. J. C. Wilson, Kluwer Academic Publishers, Boston, 1992; vol. C, pp. 219–220, table 4.2.6.8; (d) D. C. Creagh, J. H. Hubbell, in International Tables for X-Ray Crystallography, ed. A. J. C. Wilson, Kluwer Academic Publishers, Boston, 1992; vol. C, pp. 200–206, table 4.2.4.3.

8. CrystalStructure 3.8, Crystal Structure Analysis Package, Rigaku and Rigaku/Molecular Structure Corp., 2000–2006.

9. J. R. Carruthers, J. S. Rollett, P.W. Betteridge, D. Kinna, L. Pearce, A. Larsen, E. Gabe, CRYSTALS Issue 11, Chemical Crystallography Laboratory, Oxford, 1999.